Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~A subject must meet all of the following inclusion criteria to participate in the study:~* enrolled and completed HEPLISAV or Engerix-B treatment in: DV2-HBV-17 or DV2-HBV-18 and had anti-HBsAg ≥ 10 mIU/mL prior to or during DV2-HBV-18~* previously received a complete primary hepatitis B vaccine series in DV2-HBV-17 or prior to enrollment in DV2-HBV-18~* be otherwise clinically stable in the opinion of the investigator~* be able and willing to provide informed consent~Exclusion Criteria:~A subject who meets any ONE of the following exclusion criteria is not permitted to participate in the study:~* previously enrolled in DV2-HBV-18 and never obtained anti-HBsAg ≥ 10 mIU/mL~* received hepatitis B vaccine off-study after enrolling in DV2-HBV-17 or DV2-HBV-18~* has known history of autoimmune disease~* is unwilling or unable to comply with all the requirements of the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).